Athebio AG appoints Dr. Jens Hennecke to its Board of Directors
Dr. Jens Hennecke
Schlieren-Zurich, Switzerland, December 15, 2023 – The shareholders of Athebio AG, a biotech company enabling drug developers to create superior targeted therapeutics of advanced efficacy and safety by harnessing its proprietary “plug & play” Athebody® DARPin technology platform, recently elected Dr. Jens Hennecke, PhD, as new member of the Board of Directors.
Dr. Hennecke brings his wealth of experience and expertise in the biopharmaceutical industry to Athebio. He also serves as Chief Business Officer at SOTIO Biotech.
Before joining SOTIO, he operated his own business consulting firm, offering valuable insights to European biotech companies, and also served as a non-executive Director on the Board of NBE-Therapeutics AG in Basel, Switzerland.
Dr. Hennecke's notable career includes his 10-year tenure at Micromet, Inc., where he served the role of Senior Vice President of Business Development. During this time, he successfully closed several corporate deals with pharmaceutical companies, and played a key role in the company's acquisition by Amgen in 2012.
Educationally, he holds a diploma in biology from the University of Göttingen, Germany, and earned his Ph.D. from ETH Zürich, Switzerland. His postdoctoral research at Harvard University further enriches his background and deep understanding of the intricacies of translational Science, making him a valuable addition to the leadership team at Athebio AG.
Patrik Forrer, CEO, commented: “We are delighted and honored to welcome Jens to Athebio’s Board! With his broad and deep scientific and business background and his extensive experience in deal making, he will continue to bring valuable experience and know-how to Athebio. As we progress towards establishing Athebody® DARPins as “plug & play” building blocks for innovative drugs and move forward with our partnerships, Jens will play an instrumental role in shaping the future for Athebio and our partners.”
Dr. Hennecke added: “Knowing the DARPin technology since its beginnings at the University of Zurich, I believe Athebio's proprietary Athebody® DARPin platform holds tremendous potential to empower drug developers in creating industry-leading therapeutics. I am looking forward to contributing to shaping Athebio's strategy for introducing this promising technology to innovation leaders worldwide.“
For additional information, please contact us:
Phone: +41 44 508 08 28
Email: contact@athebio.com
About Athebio
Enabling superior targeted therapeutics
Athebio enables its partners to develop superior targeted therapeutics of advanced efficacy and safety and thereby increased probability of clinical success. Athebio’s proprietary “plug & play” Athebody® platform is based on clinically validated designed ankyrin repeat proteins (DARPins) and can unlock therapeutic options not easily accessible with current antibody technologies. Rather than building up its own pipeline, Athebio licenses tailor-made Athebody®️ DARPins to its partners. Athebio has brought the DARPin technology to the next level through the development of its proprietary Athebody®️ DARPin platform. These hyper-versatile binders can easily be plugged as building blocks into a broad range of existing drug modalities. Athebody®️ DARPins offer game-changing advantages for generating next-generation multi-functional therapeutics – including excellent target specificity and affinity, ease of generating multi-specificity, high stability, small size, reliable folding, species cross-reactivity, superb developability, and good freedom-to-operate prospects.